ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OCUP Ocuphire Pharma Inc

1.70
0.03 (1.80%)
After Hours
Last Updated: 19:36:10
Delayed by 15 minutes

Period:

Draw Mode:

Volume 237,555
Bid Price 1.66
Ask Price 1.75
News -
Day High 1.71

Low
1.59

52 Week Range

High
6.60

Day Low 1.59
Company Name Stock Ticker Symbol Market Type
Ocuphire Pharma Inc OCUP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 1.80% 1.70 19:36:10
Open Price Low Price High Price Close Price Prev Close
1.67 1.59 1.71 1.655 1.67
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,004 237,555 $ 1.63 $ 388,348 - 1.59 - 6.60
Last Trade Time Type Quantity Stock Price Currency
19:36:20 10 $ 1.66 USD

Ocuphire Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
87.49M 48.34M - 19.05M -9.99M -0.21 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Ocuphire Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No OCUP Message Board. Create One! See More Posts on OCUP Message Board See More Message Board Posts

Historical OCUP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.821.891.591.77221,654-0.12-6.59%
1 Month2.072.341.591.96278,709-0.37-17.87%
3 Months2.702.851.592.20226,495-1.00-37.04%
6 Months3.143.39941.592.56222,254-1.44-45.86%
1 Year5.916.601.593.59250,524-4.21-71.24%
3 Years4.587.001.594.17456,966-2.88-62.88%
5 Years5.9313.8121.594.38429,295-4.23-71.33%

Ocuphire Pharma Description

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

Your Recent History

Delayed Upgrade Clock